| Membrane transporters in drug development Nature reviews Drug discovery 9 (3), 215-236, 2010 | 3608 | 2010 |
| Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir DJ Kempf, KC Marsh, G Kumar, AD Rodrigues, JF Denissen, E McDonald, ... Antimicrobial agents and chemotherapy 41 (3), 654-660, 1997 | 549 | 1997 |
| Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. GN Kumar, AD Rodrigues, AM Buko, JF Denissen Journal of Pharmacology and Experimental Therapeutics 277 (1), 423-431, 1996 | 488 | 1996 |
| Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. AD Rodrigues Biochemical pharmacology 57 (5), 465-480, 1999 | 470 | 1999 |
| Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions BW Ogilvie, D Zhang, W Li, AD Rodrigues, AE Gipson, J Holsapple, ... Drug Metabolism and Disposition 34 (1), 191-197, 2006 | 384 | 2006 |
| Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19 T Zvyaga, SY Chang, C Chen, Z Yang, R Vuppugalla, J Hurley, ... Drug Metabolism and disposition 40 (9), 1698-1711, 2012 | 257 | 2012 |
| Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor C Tang, M Shou, Q Mei, TH Rushmore, AD Rodrigues Journal of Pharmacology and Experimental Therapeutics 293 (2), 453-459, 2000 | 217 | 2000 |
| Pharmacokinetic drug interactions involving 17α-ethinylestradiol: a new look at an old drug H Zhang, D Cui, B Wang, YH Han, P Balimane, Z Yang, M Sinz, ... Clinical pharmacokinetics 46, 133-157, 2007 | 213 | 2007 |
| Identification of the human P450 enzymes involved in lansoprazole metabolism. RE Pearce, AD Rodrigues, JA Goldstein, A Parkinson Journal of Pharmacology and Experimental Therapeutics 277 (2), 805-816, 1996 | 211 | 1996 |
| Substrate inhibition kinetics for cytochrome P450-catalyzed reactions Y Lin, P Lu, C Tang, Q Mei, G Sandig, AD Rodrigues, TH Rushmore, ... Drug Metabolism and Disposition 29 (4), 368-374, 2001 | 205 | 2001 |
| Use of in vitro human metabolism studies in drug development: an industrial perspective AD Rodrigues Biochemical pharmacology 48 (12), 2147-2156, 1994 | 187 | 1994 |
| Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions M Sinz, S Kim, Z Zhu, T Chen, M Anthony, K Dickinson, AD Rodrigues Current drug metabolism 7 (4), 375-388, 2006 | 183 | 2006 |
| Drug-drug interactions AD Rodrigues CRC Press, 2019 | 172 | 2019 |
| Oxidative metabolism of clarithromycin in the presence of human liver microsomes: major role for the cytochrome P4503A (CYP3A) subfamily AD Rodrigues, EM Roberts, DJ Mulford, Y Yao, D Ouellet Drug Metabolism and Disposition 25 (5), 623-630, 1997 | 167 | 1997 |
| Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? AD Rodrigues Drug Metabolism and Disposition 33 (11), 1567-1575, 2005 | 159 | 2005 |
| Preclinical drug metabolism in the age of high-throughput screening: an industrial perspective AD Rodrigues Pharmaceutical research 14, 1504-1510, 1997 | 154 | 1997 |
| In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in … C Tang, M Shou, TH Rushmore, Q Mei, P Sandhu, EJ Woolf, MJ Rose, ... Pharmacogenetics and genomics 11 (3), 223-235, 2001 | 152 | 2001 |
| Enzyme kinetics of cytochrome P450-mediated reactions M Shou, Y Lin, P Lu, C Tang, Q Mei, D Cui, W Tang, JS Ngui, CC Lin, ... Current drug metabolism 2 (1), 17-36, 2001 | 151 | 2001 |
| Cytochrome P450 reaction-phenotyping: an industrial perspective H Zhang, CD Davis, MW Sinz, AD Rodrigues Expert opinion on drug metabolism & toxicology 3 (5), 667-687, 2007 | 140 | 2007 |
| Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor P Lu, ML Schrag, DE Slaughter, CE Raab, M Shou, AD Rodrigues Drug Metabolism and Disposition 31 (11), 1352-1360, 2003 | 136 | 2003 |
